Resource id #3DrugId:1d00000072resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   

Drug ID: 1d00000072

Drug Name: Ambrisentan

Generic Names: Letairis

Category: Anti- Hypertensives

Legal Status: Non Opioid Prescription only drug


Indication for Mother: Category X
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Recommended Dose: The initial recommended dose is 5mg once daily with or without food. Maximum: 10mg once daily.

Recommended In: This medication is an endothelin receptor antagonist, prescribed for pulmonary atrial hypertension (high blood pressure in the lungs). The medication blocks the effects of endothelin-1 thereby decreases blood pressure in lungs. The medication also inhibits the thickening of the blood vessel.

Directions For Use: It comes as a tablet to take by mouth, with or without food.

Storage: Store it at room temperature (25C), and in an airtight container.

Dosage Forms: Tablet

Side Effects: Most common - Peripheral edema, nasal congestion, inflammation of sinuses, flushing, palpitations inflammation of nasopharynx, abdominal pain, nausea, loss of appetite, low fever, itching, constipation and difficulty in breathing.

Central Nervous System- Headache.

Blood- Decrease in hemoglobin level.

In Case of Overdose: There is no experience with overdosage of Ambrisentan. In clinical trial doses the symptoms were headache, flushing, dizziness, nausea, and nasal congestion. Massive overdosage could potentially result in hypotension that may require intervention.

Avoid If: Caution should be exercised in patients with history of liver or kidney impairment, decreased sperm count, fluid retention, during breastfeeding.

Monitor liver function, complete blood count regularly while taking this medication.

Avoid excess dosage, and abrupt withdrawal.

Contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF), pregnant women and known hypersensitivity. It should not be co-administered with cyclosporine.

Drug Interaction: Multiple dose coadministration of ambrisentan and cyclosporine resulted in an approximately 2-fold increase in ambrisentan exposure in healthy volunteers; therefore, limit the dose of ambrisentan to 5 mg once daily when coadministered with cyclosporine.

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main